➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Moodys
Express Scripts
McKesson
Colorcon

Last Updated: June 24, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Famitinib


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Famitinib?

Famitinib is an investigational drug.

There have been 31 clinical trials for Famitinib. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2020.

The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Breast Neoplasms. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Fudan University, and Sun Yat-sen University.

There are forty-two US patents protecting this investigational drug and three hundred and ninety-eight international patents.

Recent Clinical Trials for Famitinib
TitleSponsorPhase
Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical CancerJiangsu HengRui Medicine Co., Ltd.Phase 3
A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung CancerJiangsu HengRui Medicine Co., Ltd.Phase 2
Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid CarcinomaJiangsu HengRui Medicine Co., Ltd.Phase 2

See all Famitinib clinical trials

Clinical Trial Summary for Famitinib

Top disease conditions for Famitinib
Top clinical trial sponsors for Famitinib

See all Famitinib clinical trials

US Patents for Famitinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Famitinib   Try Before You Buy TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (Cambridge, MA)   Try Before You Buy
Famitinib   Try Before You Buy Substituted urea derivatives and pharmaceutical uses thereof SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN)   Try Before You Buy
Famitinib   Try Before You Buy Optimized variants of anti-VEGF antibodies and methods of treatment thereof by reducing or inhibiting angiogenesis Genentech, Inc. (South San Francisco, CA)   Try Before You Buy
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Famitinib

Drugname Country Document Number Estimated Expiration Related US Patent
Famitinib European Patent Office EP3344624 2035-09-02   Try Before You Buy
Famitinib Hong Kong HK1256997 2035-09-02   Try Before You Buy
Famitinib Japan JP2018532706 2035-09-02   Try Before You Buy
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
McKesson
Baxter
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.